Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lamivudine/tenofovir disoproxil fumarate - Mylan

Next Previous
Search
Drug Profile

Lamivudine/tenofovir disoproxil fumarate - Mylan

Alternative Names: CIMDUO; Tenofovir disoproxil fumarate/lamivudine - Mylan

Latest Information Update: 06 Dec 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mylan Laboratories Limited
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 06 Dec 2018 Launched for HIV infections (Combination therapy, In adolescents, In children, In adults) in India prior December 2018 (Mylan website, December 2018) (PO)
  • 05 Mar 2018 The label for lamivudine/tenofovir disoproxil fumarate contains a boxed warning for post-treatment acute exacerbations of hepatitis B
  • 02 Mar 2018 Mylan intends to launch lamivudine/tenofovir disoproxil fumarate in USA in Second quarter of 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top